Published in Ann Transl Med on May 01, 2016
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | NCT01968109
A Phase 1/2 Study to Evaluate MEDI4736 | NCT01693562
Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients | NCT01493154
ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer | NCT02002182
Immune Therapy of HPV-induced Cancers | NCT01462838
Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer | NCT00019110
Pembrolizumab in Combination With CRT for LA-SCCHN | NCT02586207
Dendritic Cell Vaccine for Head and Neck Cancer (Dendritic) | NCT00492947
Overview of advances in cancer immunotherapy. Ann Transl Med (2016) 0.75
A Clinically Distinct and 'Atypical' Subgroup of Head and Neck Cancers Positive for a CpG Island Methylator Phenotype. EBioMedicine (2017) 0.75
mTOR co-targeting strategies for head and neck cancer therapy. Cancer Metastasis Rev (2017) 0.75
Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study. Oral Surg Oral Med Oral Pathol Oral Radiol (2017) 0.75
Prognostic potential of KLOTHO and SFRP1 promoter methylation in head and neck squamous cell carcinoma. J Appl Genet (2017) 0.75
T-helper and T-regulatory cells modulation in head and neck squamous cell carcinoma. Oncoimmunology (2017) 0.75
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med (2008) 11.86
The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 9.39
Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol (2008) 8.17
Decoding the patterns of self and nonself by the innate immune system. Science (2002) 7.19
Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med (2003) 5.96
Mechanisms of immune evasion by tumors. Adv Immunol (2006) 5.34
Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clin Oncol (2006) 4.66
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol (2013) 4.55
Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell (2013) 3.75
Adoptive T cell therapy for cancer in the clinic. J Clin Invest (2007) 3.45
T-cell-antigen recognition and the immunological synapse. Nat Rev Immunol (2003) 3.38
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res (2013) 2.81
Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res (2006) 2.56
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine (2008) 2.48
E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst (2009) 2.45
PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res (2012) 2.43
Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin Cancer Res (2007) 2.21
Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol (2010) 2.20
Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res (2002) 2.05
Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One (2013) 2.03
Cellular constituents of immune escape within the tumor microenvironment. Cancer Res (2012) 1.75
Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer (2005) 1.69
Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res (2007) 1.59
Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem (2012) 1.57
Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res (2002) 1.45
Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol (2013) 1.38
Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer (2011) 1.35
Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother (2004) 1.34
Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology (2011) 1.28
Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res (2011) 1.22
Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PLoS One (2012) 1.21
Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol (2011) 1.15
Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma--derived CD44(+)ALDH1(+) cells. Mol Cancer Ther (2010) 1.11
Natural killer cells preferentially target cancer stem cells; role of monocytes in protection against NK cell mediated lysis of cancer stem cells. Curr Drug Deliv (2012) 1.11
Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes. Cancer Immunol Immunother (2011) 1.11
Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol (2015) 1.10
Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol Ther (2013) 1.10
Nimotuzumab with chemoradiation confers a survival advantage in treatment-naïve head and neck tumors over expressing EGFR. Cancer Biol Ther (2010) 1.08
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin Oncol (2015) 1.06
Cancer-associated fibroblasts and CD163-positive macrophages in oral squamous cell carcinoma: their clinicopathological and prognostic significance. J Oral Pathol Med (2012) 1.04
Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck. Head Neck (2007) 1.04
Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol (2005) 1.01
Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine (2008) 1.01
Rational combinations of immunotherapeutics that target discrete pathways. J Immunother Cancer (2013) 0.95
Head and neck cancer stem cells. J Dent Res (2011) 0.94
T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov (2014) 0.93
Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol (2013) 0.93
Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res (2014) 0.92
Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer (2014) 0.92
The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol (2015) 0.91
Revisiting the prognostic value of regulatory T cells in patients with cancer. J Clin Oncol (2009) 0.90
Head and neck cancer stem cells: the effect of HPV--an in vitro and mouse study. Otolaryngol Head Neck Surg (2013) 0.89
Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. Arch Otolaryngol Head Neck Surg (2000) 0.89
Biology and immunology of cancer stem(-like) cells in head and neck cancer. Crit Rev Oncol Hematol (2015) 0.88
Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma. Head Neck (2012) 0.88
CD45RA-Foxp3high but not CD45RA+Foxp3low suppressive T regulatory cells increased in the peripheral circulation of patients with head and neck squamous cell carcinoma and correlated with tumor progression. J Exp Clin Cancer Res (2014) 0.85
Tailored immunotherapy for HPV positive head and neck squamous cell cancer. Oral Oncol (2013) 0.84
High level of Tregs is a positive prognostic marker in patients with HPV-positive oral and oropharyngeal squamous cell carcinomas. Biomed Res Int (2014) 0.84
Elevated intrinsic cancer stem cell population in human papillomavirus-associated head and neck squamous cell carcinoma. Cancer (2013) 0.84
Immunity in head and neck cancer. Cancer Immunol Res (2015) 0.84
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol (2014) 0.83
Immunotherapy of human papilloma virus induced disease. Open Virol J (2012) 0.83
Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences. Br J Cancer (2014) 0.83
Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. Hum Vaccin Immunother (2016) 0.82
ALDH1-positive cancer stem-like cells are enriched in nodal metastases of oropharyngeal squamous cell carcinoma independent of HPV status. Oncol Rep (2013) 0.81
The role of immune system exhaustion on cancer cell escape and anti-tumor immune induction after irradiation. Biochim Biophys Acta (2016) 0.79
Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice. Cancer Treat Rev (2016) 0.78
Immune alterations and immunotherapy prospects in head and neck cancer. Expert Opin Biol Ther (2013) 0.78
Ten years of progress in head and neck cancers. J Natl Compr Canc Netw (2012) 0.77
Adoptive cell transfer after chemotherapy enhances survival in patients with resectable HNSCC. Int Immunopharmacol (2015) 0.77
Dendritic cell-based autologous tumor vaccines for head and neck squamous cell carcinoma. Head Neck (2015) 0.77
Immunologically augmented skin flap as a novel dendritic cell vaccine against head and neck cancer in a rat model. Cancer Sci (2015) 0.76
Immunotherapy of HPV-associated cancer: DNA/plant-derived vaccines and new orthotopic mouse models. Cancer Immunol Immunother (2015) 0.76